Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Academic Article

Abstract

  • BACKGROUND: We examined data from a Phase 2 trial {NCT00457821} of ivacaftor, a CFTR potentiator, in cystic fibrosis (CF) patients with aG551D mutation to evaluate standardized approaches to sweat chloride measurement and to explore the use of sweat chloride and nasal potential difference (NPD) to estimate CFTR activity. METHODS: Sweat chloride and NPD were secondary endpoints in this placebo-controlled, multicenter trial. Standardization of sweat collection, processing,and analysis was employed for the first time. Sweat chloride and chloride ion transport (NPD) were integrated into a model of CFTR activity. RESULTS: Within-patient sweat chloride determinations showed sufficient precision to detect differences between dose-groups and assess ivacaftor treatment effects. Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity equivalent to approximately 35%–40% of normal. CONCLUSIONS: Sweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators.
  • Authors

    Published In

    Keywords

  • Adult, Aminophenols, Biomarkers, Child, Chlorides, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Dose-Response Relationship, Drug, Double-Blind Method, Drug Monitoring, Female, Humans, Male, Mutation, Nasal Mucosa, Quinolones, Reproducibility of Results, Respiratory System Agents, Specimen Handling, Sweat, Treatment Outcome
  • Author List

  • Accurso FJ; Van Goor F; Zha J; Stone AJ; Dong Q; Ordonez CL; Rowe SM; Clancy JP; Konstan MW; Hoch HE
  • Start Page

  • 139
  • End Page

  • 147
  • Volume

  • 13
  • Issue

  • 2